However, more than 25% of early-stage ERBB2+ breast cancer patients develop resistance to trastuzumab and more than 75% late-stage ERBB2+ breast cancers are resistant to trastuzumab even if given in combination with anthracyclines. Here, ERBB2 is linked to breast carcinoma.